Abbott Laboratories - ABT Forward P/S Multiple

Corporate company logo of Abbott Corp. (ABT)

Abbott Laboratories (ABT) is actively implementing automated production lines for diagnostic devices, and P/S expectations for the company on GURU.Markets clearly demonstrate this technological leap. The value 1.80 sets the current magnitude of this metric. Growth is supported by strong pricing power in the glucose monitoring segment, while the business's status as a defensive asset guarantees revenue stability even amidst macroeconomic turmoil.

abbott.com - ABT Forward Price-to-Revenue Multiple (period 07/04/2022 - 11/13/2026)

Abbott Corp. (ABT) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price Abbott|ABT - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Abbott Corp.|ABT - Company Buyout Price
- issuer book value statistics:
Book Value per Share Abbott|ABT - Company Net Assets|Market Capitalization to Book Value Ratio abbott.com|ABT - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Abbott Laboratories|ABT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Abbott Laboratories|ABT - Aggregate Debt Obligations|Debts to Book Capitalization Abbott Corp.|ABT - Long-Term Debt|Company Short-Term Debt Abbott|Quick Liquidity Indicator abbott.com
- financial results and valuation multiples details:
ABT - Net Profit|Projected Future Earnings Abbott Laboratories|ABT - Business Payback Period|Future Price to Earnings Abbott Laboratories Inc.|ABT - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Abbott Corp.|ABT - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Abbott|ABT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months abbott.com|ABT - Earnings per share growth this year|Expected earnings per share growth for next year Abbott Laboratories
- sales and revenue data:
ABT - Company Total Sales|Projected Sales Volume Abbott|ABT - P/S Multiple|Forward P/S Multiple Abbott Corp.
Summary company analysis:Abbott ABT
Original product of abbott.com

To objectively assess asset value, a manager must correlate current market capitalization with expected revenue. This ratio measures the premium the market is willing to pay for future sales, revealing whether the business is overvalued or undervalued. By analyzing P/S expectations for Abbott Laboratories (ABT), an investor can evaluate the resilience of the stock price against FDA regulatory risks and disruptions in the supply of medtech components.

Competitor analysis

Forward P/S Multiple TMO (Thermo Fisher)|GEHC: Market Cap to Projected Revenue|Mettler-Toledo International Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Waters Technologies WAT|TECH: Forward P/S Multiple|Forward Price-to-Revenue Multiple bruker.com|AZTA (Azenta) - Forward P/S Multiple|Forward P/S Multiple Varex Imaging Corp|Price-to-Projected Revenue Ratio Semler Scientific Corp (SMLR)|Price-to-Projected Revenue Ratio BFLY (Butterfly Corp)|Mesa Laboratories, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales QSI|Nano-X - Forward P/S Multiple|Market Cap to Future Revenue Ratio Quanterix Corp.|908 Devices Corp (MASS) - Price-to-Projected Revenue Ratio|Projected Price to Revenue CapsoVision CV|Forward Price-to-Revenue Multiple MXCT|Forward P/S Multiple Rapid Micro|Forward P/S Multiple SEER|Market Cap to Expected Sales Ratio Hyperfine Inc|Price-to-Projected Revenue Ratio FONAR Corp FONR|DXR (Daxor Corp) - Future Price to Revenue|MDAI - Price-to-Projected Revenue Ratio|VivoSim Labs (VIVS) - Forward Price-to-Revenue Multiple|ACON: Forward P/S Multiple|Market Cap to Future Revenue Ratio Akoya Biosciences, Inc. (AKYA)|Price-to-Projected Revenue Ratio ThermoGenesis Holdings Inc.|Market Cap to Projected Revenue TLIS (Talis Biomedical Corp)|Forward Price-to-Revenue Multiple TTOO (T2 Biosystems, Inc.)